The cancer stem cell (SC) theory proposes that a population of SCs serves as the driving
force behind fundamental tumor processes, including metastasis, recurrence, and resistance …

The last two decades have witnessed major breakthroughs in the development of targeted
therapy for patients with metastatic colorectal cancer (mCRC), an achievement which stems …

Colorectal cancer (CRC) is the third most common malignancy worldwide. It is projected to
increase by 3.2 million new cases and account for 1.6 million deaths by 2040. Mortality is …

Although immune checkpoint inhibitors have revolutionized the treatment of several
advanced solid cancers, in colorectal cancer, the transformative benefit of these innovative …

Purpose: Genomic instability is a hallmark of cancer and targeting DNA damage response
(DDR) is emerging as a promising therapeutic strategy in different solid tumors. The …

Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide.
Chemotherapy continues to serve as the primary treatment modality, while immunotherapy …

There is emerging evidence about the predictive role of homologous recombination
deficiency (HRD), but this is less defined in gastrointestinal (GI) and thoracic malignancies …

Simple Summary Defective DNA damage response (DDR) is a hallmark of cancer leading to
genomic instability. Up to 15–20% of colorectal cancers carry alterations in DDR. However …

Homologous recombination (HR) and mismatch repair (MMR) defects are driver mutational
imprints and actionable biomarkers in DNA repair-defective tumors. Although usually …

Background Fusobacterium nucleatum (F. nucleatum) is one of the key tumorigenic bacteria
in colorectal cancer (CRC), yet how F. nucleatum is involved in colorectal cancer …